Literature DB >> 35511432

Deciphering the tumor microenvironment cell-infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC.

Hao Chen1, Tongchao Zhang1, Yuan Zhang1, Hao Wu2,3,4, Zhen Fang2,3,4, Yang Liu2,3,4, Yang Chen5, Zhe Wang6, Shengtao Jia6, Xingzhao Ji4,7, Liang Shang2,3,4, Fengying Du2,3,4, Jin Liu8, Ming Lu1, Wei Chong2,3,4.   

Abstract

Recent studies highlighted the clinicopathologic importance of the tumor microenvironment (TME) in delineating molecular attributes and therapeutic potentials. However, the overall TME cell infiltration landscape in nonsquamous non-small cell lung cancer (NSCLC) has not been comprehensively characterized. In this study, we used consensus non-negative matrix factorization molecular subtyping to determine TME cell infiltration patterns and identified 3 TME clusters (TME-C1, -C2, -C3) characterized by distinct clinicopathologic features, infiltrating cells, and biological processes. Proteomics analyses revealed that cyclic GMP-AMP-stimulator of interferon genes immune signaling-mediated protein and phosphorylation levels were significantly upregulated in inflammation-related TME-C2 clusters. The score extracted from the TME-related signature (TMEsig-score) divided patients with NSCLC into high- and low-score subgroups, where a high score was associated with favorable prognosis and immune infiltration. The genomic landscape revealed that patients with low TMEsig-score harbored more somatic copy number alterations and higher mutation frequency of driver genes involving STK11, KEAP1, SMARCA4, and others. Drug sensitivity analyses suggested that tumors with high TMEsig-score were responsible for favorable clinical response to immune checkpoint inhibitor treatment. In summary, this study highlights that comprehensive recognizing of the TME cell infiltration landscape will contribute to enhancing our understanding of TME immune regulation and promote effectiveness of precision biotherapy strategies.

Entities:  

Keywords:  Cancer immunotherapy; Genetic variation; Immunology; Lung cancer; Oncology

Mesh:

Substances:

Year:  2022        PMID: 35511432      PMCID: PMC9309061          DOI: 10.1172/jci.insight.152815

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  58 in total

1.  The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma.

Authors:  Hao Chen; Meng Yang; Qinghua Wang; Fengju Song; Xiangchun Li; Kexin Chen
Journal:  Oncoimmunology       Date:  2019-05-10       Impact factor: 8.110

Review 2.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

3.  Phenotype molding of stromal cells in the lung tumor microenvironment.

Authors:  Diether Lambrechts; Els Wauters; Bram Boeckx; Sara Aibar; David Nittner; Oliver Burton; Ayse Bassez; Herbert Decaluwé; Andreas Pircher; Kathleen Van den Eynde; Birgit Weynand; Erik Verbeken; Paul De Leyn; Adrian Liston; Johan Vansteenkiste; Peter Carmeliet; Stein Aerts; Bernard Thienpont
Journal:  Nat Med       Date:  2018-07-09       Impact factor: 53.440

4.  Inferring tumour purity and stromal and immune cell admixture from expression data.

Authors:  Kosuke Yoshihara; Maria Shahmoradgoli; Emmanuel Martínez; Rahulsimham Vegesna; Hoon Kim; Wandaliz Torres-Garcia; Victor Treviño; Hui Shen; Peter W Laird; Douglas A Levine; Scott L Carter; Gad Getz; Katherine Stemke-Hale; Gordon B Mills; Roel G W Verhaak
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

5.  Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I-III colon cancer.

Authors:  Rui Zhou; Jingwen Zhang; Dongqiang Zeng; Huiying Sun; Xiaoxiang Rong; Min Shi; Jianping Bin; Yulin Liao; Wangjun Liao
Journal:  Cancer Immunol Immunother       Date:  2018-12-19       Impact factor: 6.968

Review 6.  The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.

Authors:  Min Yuan; Li-Li Huang; Jian-Hua Chen; Jie Wu; Qing Xu
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

7.  An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma.

Authors:  Minghui Zhang; Kaibin Zhu; Haihong Pu; Zhuozhong Wang; Hongli Zhao; Jinfeng Zhang; Yan Wang
Journal:  Front Oncol       Date:  2019-12-10       Impact factor: 6.244

8.  Establishment of a Gene Signature to Predict Prognosis for Patients with Lung Adenocarcinoma.

Authors:  Zhaodong Li; Fangyuan Qi; Fan Li
Journal:  Int J Mol Sci       Date:  2020-11-11       Impact factor: 5.923

9.  Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.

Authors:  Kevin Litchfield; James L Reading; Clare Puttick; Krupa Thakkar; Chris Abbosh; Robert Bentham; Thomas B K Watkins; Rachel Rosenthal; Dhruva Biswas; Andrew Rowan; Emilia Lim; Maise Al Bakir; Virginia Turati; José Afonso Guerra-Assunção; Lucia Conde; Andrew J S Furness; Sunil Kumar Saini; Sine R Hadrup; Javier Herrero; Se-Hoon Lee; Peter Van Loo; Tariq Enver; James Larkin; Matthew D Hellmann; Samra Turajlic; Sergio A Quezada; Nicholas McGranahan; Charles Swanton
Journal:  Cell       Date:  2021-01-27       Impact factor: 41.582

10.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

View more
  1 in total

1.  Integrated multi-omics characterization of KRAS mutant colorectal cancer.

Authors:  Wei Chong; Xingyu Zhu; Huicheng Ren; Chunshui Ye; Kang Xu; Zhe Wang; Shengtao Jia; Liang Shang; Leping Li; Hao Chen
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.